Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRI-724 in Advanced Myeloid Malignancies
NCT01606579Phase 2Completed
- Sponsor
- Prism Pharmaceuticals
- Start
- Jul 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of foscenvivint in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) and 1 more (5 arms), sponsored by Prism Pharmaceuticals. Primary endpoint: Dose Limiting Toxicity at 1 year. Started Jul 2012; status: completed.
02
Drugs
foscenvivint
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT01606579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01606579.